Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).
799 United States sites
426 Brazil sites
285 Nigeria sites
240 Kenya sites
187 Turkey sites
144 Colombia sites
144 France sites
144 Italy sites
96 Lebanon sites
95 United Kingdom sites
48 Germany sites
47 Saudi Arabia sites
47 Oman sites
47 Tanzania sites
> 12 Years
Phase 3
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).
494 United States sites
266 Nigeria sites
224 Brazil sites
190 Kenya sites
190 Turkey sites
114 Italy sites
76 Colombia sites
76 Lebanon sites
72 France sites
38 Oman sites
38 Germany sites
36 Saudi Arabia sites
> 12 Years
Phase 3
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
1007 United States sites
133 United Kingdom sites
95 France sites
95 Spain sites
76 Greece sites
76 Italy sites
57 Canada sites
38 Lebanon sites
38 Germany sites
38 Oman sites
12 Years - 65 Years
Phase 2/Phase 3
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA.
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.
504 United States sites
120 Spain sites
96 Belgium sites
72 Brazil sites
72 Colombia sites
72 Germany sites
72 India sites
72 Italy sites
72 United Kingdom sites
48 Canada sites
48 Lebanon sites
48 Turkey sites
24 Oman sites
24 Switzerland sites
24 France sites
6 Months - 17 Years
Phase 2
